The ASX 200 is home to some high quality companies that have significant long term potential.
Two that have recently been rated as buys are listed below. Here’s why these ASX 200 shares could be in the buy zone:
CSL Limited (ASX: CSL)
The first ASX 200 share to look at is biotherapeutics giant CSL. Its CSL Behring and Seqirus businesses have a portfolio of life-saving and lucrative therapies and vaccines which are generating billions of dollars in sales each year.
But management never rests on its laurels. Each year it invests in the region of 10% to 11% of its sales back into research and development (R&D) activities. This means that CSL will be investing around US$1 billion into its R&D this year. This ensures that the company has pipeline of therapies under development that could drive its future growth.
In addition, CSL is in the process of acquiring Vifor Pharma for ~$17 billion. Management notes that the deal expands its leadership across an attractive portfolio focused on renal disease and iron deficiency. It also highlights that Vifor has a high quality pipeline and complements CSL’s existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.
Citi is bullish on CSL and has a buy rating and $340.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share to look at is ResMed. It is a leading sleep treatment-focused medical device company with a portfolio of products improving the lives of sufferers of conditions such as sleep apnoea.
ResMed has been growing at a solid rate for well over a decade and shows no signs of stopping any time soon. This is due to its leadership position in a market which continues to grow as education around sleep disorders improves.
In addition, with one of its key competitors continuing to work its way through a massive product recall, ResMed looks well-placed to win market share. This, combined with its patient-centric, connected-care digital platform, bodes well for its growth in the coming years.
Morgans is a big fan of the company and has an add rating and $40.46 price target on its shares.
The post 2 highly rated ASX 200 shares to buy immediately appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- Why this top broker is ‘cautious’ on the outlook for CSL (ASX:CSL) shares
- 2 ASX shares at a golden buying opportunity right now
- These ASX 200 shares can beat inflation: expert
- Expert tips 3 leading ASX 200 shares to buy on the dip
- Leading brokers name 3 ASX shares to buy today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3dVzqlH
Leave a Reply